T-cell masthead image

SGX942

Poster

Innate Defense Regulators (IDRs) – Agnostic Therapy to Treat Bacterial Infections and Fight Resistance

  • PDF (866.94 KB)
Donini O, Straube R. Host-Directed Innate Defense Regulators (IDRs) – Agnostic Therapy to Treat Bacterial Infections and Fight Resistance. Poster presentated at the 2018 ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. 2018.
Presentation

Modulation of Innate Immunity in the Treatment of Inflammation-Driven and Infection-Driven Disease

Donini O. Modulation of Innate Immunity in the Treatment of Inflammation-Driven and Infection-Driven Disease. Presentation at the 2017 Drug Discovery and Therapy World Congress Meeting. July 10-13, 2017
Paper

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

  • PDF (240.80 KB)
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Scott Z, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotech Reports. 2017; 15:24-26.
Presentation

Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease

Donini O. Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease – “Supercharging existing and new antibiotic therapies”. Presentation at the 2017 Superbugs & Superdrugs Meeting. March 20-21, 2017.
Paper

Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study

  • External Link
Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis S, Straube S, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotech 2016; 239: 115-125.
Presentation

SGX942 Reduces the Duration of Severe Oral Mucositis

  • PDF (596.55 KB)
Donini O, Straube R. SGX942 Reduces the Duration of Severe Oral Mucositis. Presentation at 2016 Multinational Association for Supportive Care in Cancer Conference. June 23-25, 2016
Poster

An Innate Defense Regulator for the Treatment of Macrophage Activation Syndrome: Preclinical Studies in an Orphan Indication

  • PDF (365.24 KB)
Donini O, Behrens E, Haulenbeek A, Pullion C, Schaber C. An Innate Defense Regulator for the Treatment of Macrophage Activation Syndrome: Preclinical Studies in an Orphan Indication. Poster Presentated at the National Organization for Rare Diseases (NORD) Rare Diseases and Orphan Products Breakthrough Summit. 2016.
Poster

SGX942 Reduces the Duration of Severe Oral Mucositis

  • PDF (147.18 KB)
Donini O, Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Elder J. SGX942 Reduces the Duration of Severe Oral Mucositis. Poster presented at the 25th Multinational Association of Supportive Care in Cancer. 2016.
Paper

A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy

  • External Link
North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici L, Finlay BB, Schaber CJ, Straube R, Donini O. A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. J Biotech 2016; 226: 24-34.
Presentation

Innate Defense Regulators as Treatment for Meliodosis

  • PDF (468.17 KB)
Donini O, Morici L. Innate Defense Regulators as Treatment for Meliodosis. Presentation at 2015 ASM Biodefense and Emerging Diseases Research Meeting. February 9-11, 2015.